Daniel Eberhard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daniel Eberhard has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Eckhard Lammert
Heinrich Heine University Düsseldorf
5 shared publications Jessica Mrugala
Heinrich-Heine-Universität Düsseldorf, Deutsches Diabetes Zentrum Düsseldorf (DDZ), Deutsches Zentrum für Diabetes Forschung (DZD), Institut für Stoffwechselphysiologie, Düsseldorf, Germany
3 shared publicationsAlena Welters
Institute of Metabolic Physiology, Heinrich Heine University, 40225 Düsseldorf, Germany; Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, 40225 Düsseldorf, Germany
2 shared publications- Bengt-Frederik Belgardt
German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine University Dusseldorf
2 shared publications - Hadi Al-Hasani
Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany
2 shared publications Laura Wörmeyer
Institute of Metabolic Physiology, Heinrich Heine University, 40225 Düsseldorf, Germany; Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, 40225 Düsseldorf, Germany
2 shared publications
Latest Publications
- Open Access
Enhancing pancreatic islet cell survival via NMDAR antagonist-driven ROR1 activation as revealed by phosphoproteomics
NMDA receptors (NMDARs) control function and survival not only of neurons, but also of insulin-producing pancreatic beta cells. Since insufficient insulin secretion and beta cell death are key events during diabetes development, targeting NMDARs offers a therapeutic approach. Specifically, the NMDAR antagonist dextrorphan (DXO) increases glucose-stimulated insulin secretion in clinical trials. Furthermore, treatment with DXO or optimized DXO derivatives prevents pancreatic islet cell death upon diabetogenic insults. Nonetheless, the signaling pathways induced by NMDAR inhibition are poorly understood. Here, we use complementary approaches, phosphoproteomics and tyrosine kinase profiling, to demonstrate that DXO and its derivatives rapidly regulate multiple intracellular signaling clusters, including mTOR and ERK signaling, in pancreatic islets. Notably, mTOR inhibition, but not ERK inhibition, is sufficient to negate DXO's protective effects. Further, we show that activation of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) is a universal event upon NMDAR inhibition in islets. Simultaneous knockdown of Ror1/ROR1 and its paralogue Ror2/ROR2 compromises the viability of both mouse and human islets, highlighting the ROR1/2 signaling axis as a promising avenue for enhancing beta cell survival.
Open AccessEnhancing pancreatic islet cell survival via NMDAR antagonist-driven ROR1 activation as revealed by phosphoproteomics
NMDA receptors (NMDARs) control function and survival not only of neurons, but also of insulin-producing pancreatic beta cells. Since insufficient insulin secretion and beta cell death are key events during diabetes development, targeting NMDARs offers a therapeutic approach. Specifically, the NMDAR antagonist dextrorphan (DXO) increases glucose-stimulated insulin secretion in clinical trials. Furthermore, treatment with DXO or optimized DXO derivatives prevents pancreatic islet cell death upon diabetogenic insults. Nonetheless, the signaling pathways induced by NMDAR inhibition are poorly understood. Here, we use complementary approaches, phosphoproteomics and tyrosine kinase profiling, to demonstrate that DXO and its derivatives rapidly regulate multiple intracellular signaling clusters, including mTOR and ERK signaling, in pancreatic islets. Notably, mTOR inhibition, but not ERK inhibition, is sufficient to negate DXO's protective effects. Further, we show that activation of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) is a universal event upon NMDAR inhibition in islets. Simultaneous knockdown of Ror1/ROR1 and its paralogue Ror2/ROR2 compromises the viability of both mouse and human islets, highlighting the ROR1/2 signaling axis as a promising avenue for enhancing beta cell survival.
- Open Access
- 5 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Identification of myeloid-derived growth factor as a mechanically-induced, growth-promoting angiocrine signal for human hepatocytes
Recently, we have shown that after partial hepatectomy (PHx), an increased hepatic blood flow initiates liver growth in mice by vasodilation and mechanically-triggered release of angiocrine signals. Here, we use mass spectrometry to identify a mechanically-induced angiocrine signal in human hepatic endothelial cells, that is, myeloid-derived growth factor (MYDGF). We show that it induces proliferation and promotes survival of primary human hepatocytes derived from different donors in two-dimensional cell culture, via activation of mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3). MYDGF also enhances proliferation of human hepatocytes in three-dimensional organoids. In vivo, genetic deletion of MYDGF decreases hepatocyte proliferation in the regenerating mouse liver after PHx; conversely, adeno-associated viral delivery of MYDGF increases hepatocyte proliferation and MAPK signaling after PHx. We conclude that MYDGF represents a mechanically-induced angiocrine signal and that it triggers growth of, and provides protection to, primary mouse and human hepatocytes.
- 5 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessIdentification of myeloid-derived growth factor as a mechanically-induced, growth-promoting angiocrine signal for human hepatocytes
Recently, we have shown that after partial hepatectomy (PHx), an increased hepatic blood flow initiates liver growth in mice by vasodilation and mechanically-triggered release of angiocrine signals. Here, we use mass spectrometry to identify a mechanically-induced angiocrine signal in human hepatic endothelial cells, that is, myeloid-derived growth factor (MYDGF). We show that it induces proliferation and promotes survival of primary human hepatocytes derived from different donors in two-dimensional cell culture, via activation of mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3). MYDGF also enhances proliferation of human hepatocytes in three-dimensional organoids. In vivo, genetic deletion of MYDGF decreases hepatocyte proliferation in the regenerating mouse liver after PHx; conversely, adeno-associated viral delivery of MYDGF increases hepatocyte proliferation and MAPK signaling after PHx. We conclude that MYDGF represents a mechanically-induced angiocrine signal and that it triggers growth of, and provides protection to, primary mouse and human hepatocytes.
- 1 April 2023
- Published by Georg Thieme Verlag KG in Diabetologie und Stoffwechsel
- Vol. 18 (S 01) , S9-S10
Pancreatic islet protection at the expense of secretory function associates with serine-linked one-carbon metabolism
Type 2 diabetes (T2D) is the most common metabolic disease worldwide and is characterized by insulin hypersecretion, followed by reduced glucose-stimulated insulin secretion (GSIS). Even though much has been discovered about insulin producing beta cell physiology, the molecular mechanisms behind beta cell decay in T2D are still unknown and no anti-diabetic drug is available to fully halt or reverse this process. Here, we show that short-term in vitro stimulation of mouse pancreatic islets with insulin secretagogue dextrorphan (DXO) enhances GSIS, but does not protect islets from cell death. In contrast, long-term insulin hypersecretion induced by DXO reduces GSIS, but protects islets from cell death. Bulk RNA sequencing of islets reveals increased expression of genes encoding enzymes of the serine-linked mitochondrial one-carbon metabolism (OCM) after long-term, but not short-term stimulation. In long-term stimulated islets, more glucose was metabolized to serine than citrate, and mitochondrial concentrations of ATP decreased, despite unaltered oxygen consumption, while NAPDH increased. Activating transcription factor-4 (Atf4) is shown to be required and sufficient to activate serine-linked mitochondrial OCM genes in islets, and gain- and loss-of-function experiments revealed that Atf4 reduces GSIS and is necessary, but not solely sufficient for full DXO-mediated islet cell protection. Furthermore, we show that de novo serine synthesis enzyme phosphoglycerate dehydrogenase (Phgdh) and enzymes of the mitochondrial OCM, such as serine hydroxymethyltransferase 2 (Shmt2) and methylenetetrahydrofolate dehydrogenase 2 (Mthfd2), reduce GSIS and regulate islet cell death. In summation, we identified a reversible metabolic pathway associated with islet cell protection at expense of secretory function. Article published online: 02 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 April 2023
- Published by Georg Thieme Verlag KG in Diabetologie und Stoffwechsel
- Vol. 18 (S 01) , S9-S10
Pancreatic islet protection at the expense of secretory function associates with serine-linked one-carbon metabolism
Type 2 diabetes (T2D) is the most common metabolic disease worldwide and is characterized by insulin hypersecretion, followed by reduced glucose-stimulated insulin secretion (GSIS). Even though much has been discovered about insulin producing beta cell physiology, the molecular mechanisms behind beta cell decay in T2D are still unknown and no anti-diabetic drug is available to fully halt or reverse this process. Here, we show that short-term in vitro stimulation of mouse pancreatic islets with insulin secretagogue dextrorphan (DXO) enhances GSIS, but does not protect islets from cell death. In contrast, long-term insulin hypersecretion induced by DXO reduces GSIS, but protects islets from cell death. Bulk RNA sequencing of islets reveals increased expression of genes encoding enzymes of the serine-linked mitochondrial one-carbon metabolism (OCM) after long-term, but not short-term stimulation. In long-term stimulated islets, more glucose was metabolized to serine than citrate, and mitochondrial concentrations of ATP decreased, despite unaltered oxygen consumption, while NAPDH increased. Activating transcription factor-4 (Atf4) is shown to be required and sufficient to activate serine-linked mitochondrial OCM genes in islets, and gain- and loss-of-function experiments revealed that Atf4 reduces GSIS and is necessary, but not solely sufficient for full DXO-mediated islet cell protection. Furthermore, we show that de novo serine synthesis enzyme phosphoglycerate dehydrogenase (Phgdh) and enzymes of the mitochondrial OCM, such as serine hydroxymethyltransferase 2 (Shmt2) and methylenetetrahydrofolate dehydrogenase 2 (Mthfd2), reduce GSIS and regulate islet cell death. In summation, we identified a reversible metabolic pathway associated with islet cell protection at expense of secretory function. Article published online: 02 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 October 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (10) , 1474-1488.e7
Peripherally active dextromethorphan derivatives lower blood glucose levels by targeting pancreatic islets
- 1 October 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (10) , 1474-1488.e7
Peripherally active dextromethorphan derivatives lower blood glucose levels by targeting pancreatic islets
- 7 September 2017
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (S1) , 95-106
NMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions
Diabetes mellitus is characterized by chronically elevated blood glucose levels accelerated by a progressive decline of insulin‐producing β‐cells in the pancreatic islets. Although medications are available to transiently adjust blood glucose to normal levels, the effects of current drugs are limited when it comes to preservation of a critical mass of functional β‐cells to sustainably maintain normoglycemia. In this review, we recapitulate recent evidence on the role of pancreatic N‐methyl‐D‐aspartate receptors (NMDARs) in β‐cell physiology, and summarize effects of morphinan‐based NMDAR antagonists that are beneficial for insulin secretion, glucose tolerance and islet cell survival. We further discuss NMDAR‐mediated molecular pathways relevant for neuronal cell survival, which may also be important for the preservation of β‐cell function and mass. Finally, we summarize the literature for evidence on the role of NMDARs in the development of diabetic long‐term complications, and highlight beneficial pharmacologic aspects of NMDAR antagonists in diabetic nephropathy, retinopathy as well as neuropathy.
- 7 September 2017
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (S1) , 95-106
NMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions
Diabetes mellitus is characterized by chronically elevated blood glucose levels accelerated by a progressive decline of insulin‐producing β‐cells in the pancreatic islets. Although medications are available to transiently adjust blood glucose to normal levels, the effects of current drugs are limited when it comes to preservation of a critical mass of functional β‐cells to sustainably maintain normoglycemia. In this review, we recapitulate recent evidence on the role of pancreatic N‐methyl‐D‐aspartate receptors (NMDARs) in β‐cell physiology, and summarize effects of morphinan‐based NMDAR antagonists that are beneficial for insulin secretion, glucose tolerance and islet cell survival. We further discuss NMDAR‐mediated molecular pathways relevant for neuronal cell survival, which may also be important for the preservation of β‐cell function and mass. Finally, we summarize the literature for evidence on the role of NMDARs in the development of diabetic long‐term complications, and highlight beneficial pharmacologic aspects of NMDAR antagonists in diabetic nephropathy, retinopathy as well as neuropathy.
- Open Access
- 21 August 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (8) , e105349
FTO Is a Relevant Factor for the Development of the Metabolic Syndrome in Mice
The metabolic syndrome is a worldwide problem mainly caused by obesity. FTO was found to be a obesity-risk gene in humans and FTO deficiency in mice led to reduction in adipose tissue. Thus, FTO is an important factor for the development of obesity. Leptin-deficient mice are a well characterized model for analysing the metabolic syndrome. To determine the relevance of FTO for the development of the metabolic syndrome we analysed different parameters in combined homozygous deficient mice (Lepob/ob;Fto−/−). Lepob/ob;Fto−/− mice showed an improvement in analysed hallmarks of the metabolic syndrome in comparison to leptin-deficient mice wild type or heterozygous for Fto. Lepob/ob;Fto−/− mice did not develop hyperglycaemia and showed an improved glucose tolerance. Furthermore, extension of beta-cell mass was prevented in Lepob/ob;Fto−/−mice and accumulation of ectopic fat in the liver was reduced. In conclusion this study demonstrates that FTO deficiency has a protective effect not only on the development of obesity but also on the metabolic syndrome. Thus, FTO plays an important role in the development of metabolic disorders and is an interesting target for therapeutic agents.
- 21 August 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (8) , e105349
Open AccessFTO Is a Relevant Factor for the Development of the Metabolic Syndrome in Mice
The metabolic syndrome is a worldwide problem mainly caused by obesity. FTO was found to be a obesity-risk gene in humans and FTO deficiency in mice led to reduction in adipose tissue. Thus, FTO is an important factor for the development of obesity. Leptin-deficient mice are a well characterized model for analysing the metabolic syndrome. To determine the relevance of FTO for the development of the metabolic syndrome we analysed different parameters in combined homozygous deficient mice (Lepob/ob;Fto−/−). Lepob/ob;Fto−/− mice showed an improvement in analysed hallmarks of the metabolic syndrome in comparison to leptin-deficient mice wild type or heterozygous for Fto. Lepob/ob;Fto−/− mice did not develop hyperglycaemia and showed an improved glucose tolerance. Furthermore, extension of beta-cell mass was prevented in Lepob/ob;Fto−/−mice and accumulation of ectopic fat in the liver was reduced. In conclusion this study demonstrates that FTO deficiency has a protective effect not only on the development of obesity but also on the metabolic syndrome. Thus, FTO plays an important role in the development of metabolic disorders and is an interesting target for therapeutic agents.